Shattuck Labs Revenue and Competitors
Estimated Revenue & Valuation
- Shattuck Labs's estimated annual revenue is currently $1.3M per year.
- Shattuck Labs's estimated revenue per employee is $14,222
- Shattuck Labs's total funding is $175M.
- Shattuck Labs's current valuation is $308.4M. (January 2022)
Employee Data
- Shattuck Labs has 90 Employees.
- Shattuck Labs grew their employee count by -10% last year.
Shattuck Labs Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 200% | N/A | N/A |
#2 | $15.8M | 102 | 34% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $2.8M | 18 | -25% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.6M | 15 | 50% | N/A | N/A |
#7 | $7.6M | 49 | 23% | N/A | N/A |
#8 | $0.9M | 6 | -33% | N/A | N/A |
#9 | $1.6M | 10 | -9% | N/A | N/A |
#10 | N/A | 86 | 62% | N/A | N/A |
What Is Shattuck Labs?
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARCￃﾢ￢ﾀﾞￂﾢ) platform to develop a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and inflammatory diseases. Using its ARCￃﾢ￢ﾀﾞￂﾢ platform, Shattuck is building a pipeline of therapeutics, that consolidate checkpoint blockade and TNF receptor agonists into single therapeutics to improve outcomes for patients. Shattuck has offices in Austin, Texas and Durham, North Carolina.
keywords:N/A
$175M
Total Funding
90
Number of Employees
$1.3M
Revenue (est)
-10%
Employee Growth %
$308.4M
Valuation
N/A
Accelerator
Shattuck Labs's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Technical Officer | |
2 | Chief Business Officer | |
3 | VP Translational Medicine | |
4 | SVP, Quality | |
5 | Associate Director | |
6 | Paralegal | |
7 | Senior Director, Finance, Planning & Analysis | |
8 | Associate Director External Manufacturing | |
9 | VP Biometrics | |
10 | Executive Director Clinical Research |
Shattuck Labs News
Vallon, Shattuck Labs top healthcare gainers; Babylon, SCYNEXIS lead losers' pack. Apr. 22, 2022 10:04 AM ETHCA, SCYX, VLON, STTK, ESTA, INVO, NOVN, BBLN,...
About Shattuck Labs, Inc. Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-...
AUSTIN, TX and DURHAM, NC, April 08, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology...
Shattuck Labs, a biotech startup co-located in Austin and Durham, N.C., has raised a $118 million Series B investment to continue developing cancer-fighting treatments, the company announced Monday. San Francisco-based health care investment firm Redmile Group led the round. The company had pre ...
Shattuck Labs, Inc., a Durham, North Carolina and Austin, Texas-based clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of biologic medicines for the treatment of cancer and autoimmune disease, closed a $118m Ser ...
Other Companies in Austin
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $9.2M | 90 | 13% | N/A |
#2 | $11.7M | 90 | N/A | N/A |
#3 | $14M | 90 | -18% | N/A |
#4 | $15.8M | 90 | 15% | N/A |
#5 | $24.3M | 90 | 7% | N/A |